trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['breast', 't-dxd', 'enhertu', 'bcsm', 'destiny,breast,2', 'destiny,breast,4']
t-dxd (enhertu) prolongs the time to deterioration of global health status compared to regular chemotherapy in her2 low metastatic breast cancer. patients' perspective of the balance of efficacy and safety is crucial in cancer treatment. destiny breast-04. #bcsm #esmo22 
MD Anderson Cancer Ctr, Breast Med Oncologist, Section Chief of Translational Breast Cancer Research, Executive Director of IBC Program